Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)

PASSPORT Study Group

doi:10.1038/s41591-022-02076-8

Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)

PASSPORT Study Group

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the version of this article initially published, members of the PASSPORT Study Group were listed in Supplementary information but not included in the main article. The contributors are listed below for inclusion in authorship.

Original language	English (US)
Journal	Nature Medicine
DOIs	https://doi.org/10.1038/s41591-022-02076-8
State	Accepted/In press - 2022

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1038/s41591-022-02076-8

Fingerprint

Dive into the research topics of 'Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)'. Together they form a unique fingerprint.

Cite this

@article{b90844a1eb6f49aa80f92b1740854d94,

title = "Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)",

abstract = "In the version of this article initially published, members of the PASSPORT Study Group were listed in Supplementary information but not included in the main article. The contributors are listed below for inclusion in authorship.",

author = "{PASSPORT Study Group} and Tien Dam and Boxer, {Adam L.} and Golbe, {Lawrence I.} and H{\"o}glinger, {G{\"u}nter U.} and Morris, {Huw R.} and Irene Litvan and Lang, {Anthony E.} and Corvol, {Jean Christophe} and Ikuko Aiba and Michael Grundman and Lili Yang and Beth Tidemann-Miller and Joseph Kupferman and Kristine Harper and Kubra Kamisoglu and Wald, {Michael J.} and Graham, {Danielle L.} and Liz Gedney and John O{\textquoteright}Gorman and Haeberlein, {Samantha Budd} and Ikuko Aiba and Angelo Antonini and Diana Apetauerova and Azulay, {Jean Philippe} and Martinez, {Ernest Balaguer} and Jee Bang and Paolo Barone and Matthew Barrett and Danny Bega and Daniela Berg and Corrales, {Koldo Berganzo} and Yvette Bordelon and Boxer, {Adam L.} and Moritz Brandt and Norbert Brueggemann and Giovanni Castelnovo and Roberto Ceravolo and Rosalind Chuang and Chung, {Sun Ju} and Alistair Church and Corvol, {Jean Christophe} and Paola Cudia and Marian Dale and Luc Defebvre and Sophie Drapier and Driver-Dunckley, {Erika D.} and Georg Ebersbach and Eggert, {Karla M.} and Aaron Ellenbogen and Alexandre Eusebio",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature America, Inc. 2022.",

year = "2022",

doi = "10.1038/s41591-022-02076-8",

language = "English (US)",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Author Correction

T2 - Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)

AU - PASSPORT Study Group

AU - Dam, Tien

AU - Boxer, Adam L.

AU - Golbe, Lawrence I.

AU - Höglinger, Günter U.

AU - Morris, Huw R.

AU - Litvan, Irene

AU - Lang, Anthony E.

AU - Corvol, Jean Christophe

AU - Aiba, Ikuko

AU - Grundman, Michael

AU - Yang, Lili

AU - Tidemann-Miller, Beth

AU - Kupferman, Joseph

AU - Harper, Kristine

AU - Kamisoglu, Kubra

AU - Wald, Michael J.

AU - Graham, Danielle L.

AU - Gedney, Liz

AU - O’Gorman, John

AU - Haeberlein, Samantha Budd

AU - Aiba, Ikuko

AU - Antonini, Angelo

AU - Apetauerova, Diana

AU - Azulay, Jean Philippe

AU - Martinez, Ernest Balaguer

AU - Bang, Jee

AU - Barone, Paolo

AU - Barrett, Matthew

AU - Bega, Danny

AU - Berg, Daniela

AU - Corrales, Koldo Berganzo

AU - Bordelon, Yvette

AU - Boxer, Adam L.

AU - Brandt, Moritz

AU - Brueggemann, Norbert

AU - Castelnovo, Giovanni

AU - Ceravolo, Roberto

AU - Chuang, Rosalind

AU - Chung, Sun Ju

AU - Church, Alistair

AU - Corvol, Jean Christophe

AU - Cudia, Paola

AU - Dale, Marian

AU - Defebvre, Luc

AU - Drapier, Sophie

AU - Driver-Dunckley, Erika D.

AU - Ebersbach, Georg

AU - Eggert, Karla M.

AU - Ellenbogen, Aaron

AU - Eusebio, Alexandre

PY - 2022

Y1 - 2022

N2 - In the version of this article initially published, members of the PASSPORT Study Group were listed in Supplementary information but not included in the main article. The contributors are listed below for inclusion in authorship.

AB - In the version of this article initially published, members of the PASSPORT Study Group were listed in Supplementary information but not included in the main article. The contributors are listed below for inclusion in authorship.

UR - http://www.scopus.com/inward/record.url?scp=85140853350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140853350&partnerID=8YFLogxK

U2 - 10.1038/s41591-022-02076-8

DO - 10.1038/s41591-022-02076-8

M3 - Comment/debate

C2 - 36253611

AN - SCOPUS:85140853350

SN - 1078-8956

JO - Nature Medicine

JF - Nature Medicine

ER -

Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this